Turn Biotechnologies Expands With ARMMs Acquisition
Deal News | Mar 26, 2025 | PR Newswire Cision Turn Biotechnologies, Inc.
Turn Biotechnologies, a company known for its work in epigenetic reprogramming, has announced the acquisition of ARMMs (ARRDC1 Mediated Microvesicles) technology from Vesigen Therapeutics and Harvard University. ARMMs enhance Turn Bio's epigenetic therapy capabilities, enabling broader, precise, and scalable treatment options across various tissues. This strategic acquisition complements Turn Bio’s existing eTurna LNP platform and is set to significantly advance their drug candidate pipeline in areas like ophthalmology and immune cell rejuvenation. CEO Anja Krammer noted the potential of ARMMs to further regenerative medicine by expanding the delivery of diverse therapies, including protein and gene editing technologies. This has attracted interest from leading investors such as Bayer Healthcare, Morningside Group, and Alexandria Ventures. Turn Bio aims to redefine regenerative medicine using these groundbreaking platforms to treat a variety of conditions linked to aging, such as skin aging and muscle wasting.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – Turn Biotechnologies is based in Mountain View, California, and acquired technology from Vesigen Therapeutics, located in Cambridge, Massachusetts.
Industry
- Biotechnology – Turn Biotechnologies operates in the biotechnology sector, focusing on developing therapeutic technologies for aging-related conditions through epigenetic reprogramming.
- Pharmaceuticals – The company is involved in the development of drug candidates targeting ophthalmic, dermatologic, and immune therapies, placing it within the pharmaceuticals industry.
- Healthcare – The intended use of ARMMs tech to expand therapeutic reach aligns with advancements in healthcare, particularly in precision medicine.
Financials
- – The financial details of the acquisition deal were not specified.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Turn Biotechnologies | Target company | Company | A pre-clinical-stage biotechnology company focused on repairing tissue using epigenetic reprogramming. |
| Vesigen Therapeutics | Selling company | Company | A company that developed ARMMs technology under a license from Harvard University. |
| Harvard University | Innovator | Government | Collaborated on developing ARMMs technology, providing the initial license to Vesigen Therapeutics. |
| Anja Krammer | CEO | Person | CEO of Turn Biotechnologies expressing strategic insights on the acquisition. |
| Jim Martinez | PR Contact | Person | Point of contact for public relations inquiries at Turn Biotechnologies. |
| Bayer Healthcare LLC | Investor | Company | One of the investors showing interest in ARMMs technology. |
| Morningside Group Ltd. | Investor | Company | Another investor interested in the ARMMs technology. |
| Alexandria Ventures | Investor | Company | Invested or interested in backing the application of ARMMs technology. |